BioCentury | Dec 31, 2020
Regulation

Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis

...issued feedback on proposed modifications to address COVID-related impacts to a Phase III study in osteoarthritis...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

...Claire Quang, Staff Writer DISEASE CATEGORY: MusculoskeletalINDICATION: OsteoarthritisInhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis...
...reduced expression of COL2A1 and cartilage-degrading enzymes ADAMTS4 and ADAMTS5. In a mouse model of osteoarthritis...
...Dell’Accio, same affiliation as aboveemail: fdellaccio@gmail.com Claire Quang Queen Mary University of London Receptor tyrosine kinase-like orphan receptor 2 (ROR2) Autoimmune Osteoarthritis...
BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

...raised nearly $1.7 billion towards its year-end goal of $2 billion for COVAX AMC.Novartis gains Phase II-ready osteoarthritis...
...Merck KGaANovartis AG (NYSE:NVS; SIX:NOVN) in-licensed development and commercialization rights to M6495, a Phase II-ready osteoarthritis...
BioCentury | Oct 3, 2020
Product Development

How virtual drug launches could change the biopharma industry

...part because the long-acting steroid injection for osteoarthritis...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Small molecule kinase inhibitor for cystic fibrosis with splicing mutation

...and DYRK1A, in Phase III testing for osteoarthritis...
BioCentury | Aug 18, 2020
Product Development

Unity outlines path forward for anti-aging programs after Phase II osteoarthritis failure

...cap By Virginia Li, Associate Editor  After the failure of its lead anti-aging program in osteoarthritis...
...WOMAC-A vs. placebo in a Phase II study of patients with moderate to severe painful osteoarthritis...
...the eye. We’re arranging resources to go after many things at once.”In the case of osteoarthritis...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...this week. Regeneron’s osteoarthritis mAb meets in two pivotal trials Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said osteoarthritis...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

...AstraZeneca plc (LSE:AZN; NYSE:AZN) has the PAR2 antagonist mAb MEDI0618 in Phase I testing for osteoarthritis...
BioCentury | Jul 15, 2020
Finance

Pandemic-generated demand behind strong sales of Flexion’s osteoarthritic drug

...report an unexpected boost in sales during the COVID-19 pandemic with second quarter sales for osteoarthritis...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

...FGF18. Merck KGaA (Xetra:MRK) has completed Phase II testing of recombinant FGF18 sprifermin (AS902330) for osteoarthritis...
Items per page:
1 - 10 of 1859
BioCentury | Dec 31, 2020
Regulation

Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis

...issued feedback on proposed modifications to address COVID-related impacts to a Phase III study in osteoarthritis...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

...Claire Quang, Staff Writer DISEASE CATEGORY: MusculoskeletalINDICATION: OsteoarthritisInhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis...
...reduced expression of COL2A1 and cartilage-degrading enzymes ADAMTS4 and ADAMTS5. In a mouse model of osteoarthritis...
...Dell’Accio, same affiliation as aboveemail: fdellaccio@gmail.com Claire Quang Queen Mary University of London Receptor tyrosine kinase-like orphan receptor 2 (ROR2) Autoimmune Osteoarthritis...
BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

...raised nearly $1.7 billion towards its year-end goal of $2 billion for COVAX AMC.Novartis gains Phase II-ready osteoarthritis...
...Merck KGaANovartis AG (NYSE:NVS; SIX:NOVN) in-licensed development and commercialization rights to M6495, a Phase II-ready osteoarthritis...
BioCentury | Oct 3, 2020
Product Development

How virtual drug launches could change the biopharma industry

...part because the long-acting steroid injection for osteoarthritis...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Small molecule kinase inhibitor for cystic fibrosis with splicing mutation

...and DYRK1A, in Phase III testing for osteoarthritis...
BioCentury | Aug 18, 2020
Product Development

Unity outlines path forward for anti-aging programs after Phase II osteoarthritis failure

...cap By Virginia Li, Associate Editor  After the failure of its lead anti-aging program in osteoarthritis...
...WOMAC-A vs. placebo in a Phase II study of patients with moderate to severe painful osteoarthritis...
...the eye. We’re arranging resources to go after many things at once.”In the case of osteoarthritis...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...this week. Regeneron’s osteoarthritis mAb meets in two pivotal trials Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said osteoarthritis...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

...AstraZeneca plc (LSE:AZN; NYSE:AZN) has the PAR2 antagonist mAb MEDI0618 in Phase I testing for osteoarthritis...
BioCentury | Jul 15, 2020
Finance

Pandemic-generated demand behind strong sales of Flexion’s osteoarthritic drug

...report an unexpected boost in sales during the COVID-19 pandemic with second quarter sales for osteoarthritis...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

...FGF18. Merck KGaA (Xetra:MRK) has completed Phase II testing of recombinant FGF18 sprifermin (AS902330) for osteoarthritis...
Items per page:
1 - 10 of 1859